Tempus ECG-Low EF vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A is designed to identify patients at risk of heart failure by analyzing ECGs for signs of low left ventricular ejection fraction, providing a binary output. In contrast, Tool B screens for cardiac amyloidosis by analyzing echocardiogram video clips, yielding a 'suggestive' or 'not suggestive' output. While both are FDA-cleared AI tools in cardiology, their differing input modalities and specific target conditions mean they address distinct clinical needs within the broader field of cardiac diagnostics.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-Low EF is designed to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. EchoGo Amyloidosis is an AI-powered screening tool that aids in the early detection of cardiac amyloidosis from echocardiogram video clips.
Tempus ECG-Low EF analyzes resting, non-ambulatory 12-lead ECG recordings. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically requiring a single apical 4-chamber echo video clip.
Tempus ECG-Low EF provides a binary output of 'Low LVEF Detected' or 'Not Detected', which aids clinicians in further evaluation but does not represent a diagnosis of low LVEF. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis.
Tempus ECG-Low EF is intended for use in Cardiology, Emergency Medicine, and Internal Medicine. EchoGo Amyloidosis is primarily intended for Cardiology.
EchoGo Amyloidosis reports high diagnostic accuracy with 85% sensitivity and 93% specificity, demonstrating consistent performance across CA subtypes. Tempus ECG-Low EF was trained on a large dataset of over 930,000 ECGs from more than 170,000 patients, and for positive results, LVEF u226440% was observed in approximately two in five patients when tested by echocardiogram.
More Comparisons
Backers
Who funded each tool's parent company.